Horizon (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).

Autores: Mateos, M. V.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Rodríguez Otero, Paula; Leleu, X.; Hiemenz, J. W.; Hassoun, H.; Touzeau, C.; Alegre, A.; Paner, A.; Maisel, C.; Mazumder, A.; Raptis, A.; Harmenberg, J.; Zavisic, S.; Thuresson, S.; Ohman, O.; Richardson, P. G.